1. Home
  2. NLOP vs SGMT Comparison

NLOP vs SGMT Comparison

Compare NLOP & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NLOP

Net Lease Office Properties of Beneficial Interest

HOLD

Current Price

$13.22

Market Cap

198.4M

Sector

N/A

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$8.44

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NLOP
SGMT
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
198.4M
169.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
NLOP
SGMT
Price
$13.22
$8.44
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.38
AVG Volume (30 Days)
173.9K
2.2M
Earning Date
05-19-2026
05-14-2026
Dividend Yield
51.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$118,915,000.00
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.24
$3.15
52 Week High
$34.53
$11.41

Technical Indicators

Market Signals
Indicator
NLOP
SGMT
Relative Strength Index (RSI) 53.24 76.39
Support Level $12.76 $6.17
Resistance Level $14.70 $9.02
Average True Range (ATR) 0.28 0.56
MACD 0.24 0.27
Stochastic Oscillator 91.74 86.25

Price Performance

Historical Comparison
NLOP
SGMT

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: